Brentuximab Vedotin: A New Standard of Care Across All Lines of Therapy for Hodgkin Lymphoma - Cancer Therapy Advisor

Brentuximab Vedotin: A New Standard of Care Across All Lines of Therapy for Hodgkin Lymphoma

Chapter 1

High-Risk Hodgkin Lymphoma: Staging, Biologic Markers, and Management With Brentuximab Vedotin

Patrick J. Stiff, MD, of the Cardinal Bernardin Cancer Center in Maywood, Illinois, provides an overview of the staging, biologic markers, and other factors tied to risk for recurrence in patients with Hodgkin disease, and highlights the long-term remission achieved for many patients who received brentuximab vedotin.

Chapter 2

Relapsed/Refractory Hodgkin Lymphoma: Preventing Recurrence and Need for Allogeneic Transplantation

Jeffrey Schriber, MD, FRCP, of the Cancer Transplant Institute of Arizona Oncology in Scottsdale, Arizona, underscores the role of brentuximab vedotin, in combination with autologous hematopoietic stem cell transplantation, in preventing the recurrence of Hodgkin lymphoma, and obviating the need for allogeneic transplantation.

Chapter 4

The AETHERA Trial: Reducing the Risk for Recurrence

John W. Sweetenham, MD, Senior Director of Clinical Affairs at the Huntsman Cancer Institute, University of Utah in Salt Lake City, Utah, analyses the results of the pivotal AETHERA trial of brentuximab vedotin for patients with Hodgkin lymphoma who are at risk of relapse following an autologous stem cell transplant.

Next hm-playlist in Lymphoma